Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions
Open Access
- 4 March 2023
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 5 (7) , 1870-1889
Abstract
The World Health Organisation (WHO) estimates 15 million babies worldwide are born preterm each year, with 1 million infant mortalities and long-term morbidity in survivors. Whilst the past 40 years have provided some understanding in the causes of preterm birth, along with development of a range of therapeutic options, notably prophylactic use of progesterone or uterine contraction suppressants (tocolytics), the number of preterm births continues to rise. Existing therapeutics used to control uterine contractions are restricted in their clinical use due to pharmacological drawbacks such as poor potency, transfer of drugs to the fetus across the placenta and maternal side effects from activity in other maternal systems. This review focuses on addressing the urgent need for the development of alternative therapeutic systems with improved efficacy and safety for the treatment of preterm birth. We discuss the application of nanomedicine as a viable opportunity to engineer pre-existing tocolytic agents and progestogens into nanoformulations, to improve their efficacy and address current drawbacks to their use. We review different nanomedicines including liposomes, lipid-based carriers, polymers and nanosuspensions highlighting where possible, where these technologies have already been exploited e.g. liposomes, and their significance in improving the properties of pre-existing therapeutic agents within the field of obstetrics. We also highlight where active pharmaceutical agents (APIs) with tocolytic properties have been used for other clinical indications and how these could inform the design of future therapeutics or be repurposed to diversify their application such as for use in preterm birth. Finally we outline and discuss the future challenges.Keywords
This publication has 153 references indexed in Scilit:
- Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic CombinationsPharmaceuticals, 2013
- Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: PregledActa Pharmaceutica, 2012
- Tocolytic therapy for preterm delivery: systematic review and network meta-analysisBMJ, 2012
- Liposome Technology for Industrial PurposesJournal of Drug Delivery, 2010
- [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft modelNuclear Medicine and Biology, 2009
- Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that “Slip” through the Human Mucus BarrierAngewandte Chemie International Edition, 2008
- The management of preterm labourArchives of Disease in Childhood - Fetal and Neonatal Edition, 2007
- Use of tocolytics: what is the benefit of gaining even more time?BJOG: An International Journal of Obstetrics & Gynaecology, 2006
- Childbirth Education for Multiple PregnancyThe Journal of Perinatal Education, 2005
- Indomethacin Tocolysis Increases Postnatal Patent Ductus Arteriosus SeverityPediatrics, 1998